65,437 trials
Urethritis
Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants
Asthma
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose for Each Treatment — 2.97; 2.93; 2.91; 2.77 Liters
Vasomotor Symptoms
Primary: Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4 — -6.52; -3.64 Hot Flushes — p=<0.001
Asthma
Primary: Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec — 19.8; 55.2 L/sec
Heart Defects, Congenital
Primary: Number of Participants With Bleeding Events — 0; 2; 0; 0 participants
Fibromyalgia
Primary: Summary of Most Frequent Adverse Events (Per Arm) Experienced by Study Subjects — 20; 21; 21; 23 participants
Cluster Headache
Primary: Prevalence of Allodynia in Subjects With Cluster Headache — 20 participants
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events — 186; 93; 208; 112 participants
Screening
Primary: Number of Physicians (=Participants) Recommending the Screening — 301 participants — p=<0.05
Epilepsy
Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240
Fatigue · End Stage Renal Disease (ESRD)
Primary: Reduction in Endotoxin Levels. — 5; 5 Participants
Herpes Zoster
Primary: Number of Participants With Serious Adverse Events (SAE) — 21; 11 Participants
Otitis Media, Serous · Negative Middle Ear Pressure · Rhinitis
Primary: Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment — 7; 12 participants — p=0.18
Renal Transplantation
Primary: The Number of Participants Who Responded to the Conversion to Mycophenolate Sodium (EC-MPS) Therapy — 123; 109; 74; 88 Participants
Transfusional Iron Overload · β-thalassemia Major · Pediatric Rare Anemia
Primary: Participants With Adverse Events by Primary System Organ Class (SOC) — 20; 20; 19; 20 participants